Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

5.305 +0.035 (+0.66%)
Streaming Delayed Price Updated: 3:37 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 Next >
BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
The biotech's third quarter was a good one, once you look past the top-line numbers. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular session. iRhythm Technologies's stock is trading at... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced... 
Via Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tenet Healthcare (NYSE:THC) stock r... 
Via Benzinga
2 Super-Charged Growth Stocks to Buy Now
These two small drugmakers are poised for a long-winded growth spurt. 
Via The Motley Fool
NICE Recommends BioCryst's Hereditary Angioedema Med
The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat)... 
Via Benzinga
US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (... 
Via Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Monday. The stock price moved down to $15.44 following the option alert. Sentiment: BULLISH... 
Via Benzinga
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The... 
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also... 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2021 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why BioCryst Pharmaceuticals Rose 8% on Thursday
The company's first commercial drug launch keeps exceeding expectations. 
Via The Motley Fool
Topics Earnings
Exposures Financial Product Safety
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021
Upgrades For SolarEdge Technologies Inc (NASDAQ: 
Via Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Thursday. The stock price moved up to $16.93 following the option alert. Sentiment: BULLISH... 
Via Benzinga
Unusual Options Activity Insight: BioCryst Pharmaceuticals
On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $17.1. Sentiment: BULLISH Option... 
Via Benzinga
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor,... 
Via Benzinga
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in... 
Via Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.